Soleno Therapeutics (NASDAQ:SLNO) Shares Down 7.2% – Here’s Why

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) dropped 7.2% during mid-day trading on Friday . The stock traded as low as $30.03 and last traded at $29.5780. Approximately 201,076 shares traded hands during trading, a decline of 87% from the average daily volume of 1,588,168 shares. The stock had previously closed at $31.86.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Negative Sentiment: Multiple law firms have filed or publicized class-action claims alleging investors were harmed by Soleno’s statements around its DCCR program; these filings heighten litigation risk and market uncertainty, pressuring the stock. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple plaintiff firms (Rosen, Faruqi & Faruqi, Bernstein Liebhard, Kessler Topaz, Robbins Geller, et al.) are soliciting lead plaintiffs and reminding investors of the May 5, 2026 deadline — increased media/legal attention can prompt selling and weigh on sentiment. SLNO INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
• Negative Sentiment: The alleged catalyst cited across filings is the company’s November 5, 2025 disclosure about disappointing information and launch disruptions for DCCR (VYKAT™ XR); plaintiffs claim misstatements or omissions regarding the drug’s safety/timeline, which could lead to damages, regulatory scrutiny, and distraction from commercial execution. SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on SLNO shares. Zacks Research cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Wall Street Zen downgraded Soleno Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. HC Wainwright cut their price target on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Oppenheimer reduced their price objective on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating for the company in a research report on Wednesday, March 18th. Finally, Wells Fargo & Company decreased their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $102.60.

Soleno Therapeutics Trading Down 6.0%

The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. The business’s 50-day moving average is $38.77 and its two-hundred day moving average is $48.95. The firm has a market cap of $1.55 billion, a P/E ratio of 129.77 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. As a group, analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SLNO. Avoro Capital Advisors LLC increased its position in shares of Soleno Therapeutics by 12.5% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock worth $134,270,000 after purchasing an additional 322,223 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Soleno Therapeutics in the 4th quarter valued at approximately $38,000. Seven Fleet Capital Management LP bought a new position in shares of Soleno Therapeutics in the fourth quarter valued at $6,023,000. Virtu Financial LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter valued at $1,059,000. Finally, Empowered Funds LLC acquired a new position in Soleno Therapeutics during the fourth quarter worth $69,000. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.